X80 / RADiant / PhotoElectric Therapy System (RADiant Aura)

K230611 · Xstrahl, Ltd. · JAD · Jul 13, 2023 · Radiology

Device Facts

• Record ID: K230611
• Device Name: X80 / RADiant / PhotoElectric Therapy System (RADiant Aura)
• Applicant: Xstrahl, Ltd.
• Product Code: JAD · Radiology
• Decision Date: Jul 13, 2023
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 892.5900
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Xstrahl Photoelectric Therapy System is a low energy X-Ray system intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Device Story

The RADiant Aura is a compact, floor-mounted superficial X-ray therapy system (10-80kV) for treating skin neoplasms and keloids. It comprises an X-ray therapy unit, a TP2 Central Control Unit (CCU), a Control POD, and a PC with user interface software. The system uses treatment filters and applicators to deliver radiation. It is operated by trained professionals (radiographers, clinicians, oncologists) in a shielded clinical environment. The operator controls the system from a separate control room. The device features an ergonomic support arm with electromagnetic brakes and gas struts for precise positioning of the X-ray tube head. The system provides time-based control of radiation delivery. By enabling precise, localized superficial radiotherapy, the device allows for effective treatment of skin lesions while minimizing exposure to surrounding healthy tissue.

Clinical Evidence

Bench testing only. Verification and validation included 26 independent verification tests and 18 validation tests covering mechanical stability, radiation leakage, applicator/filter retention, and system response to power loss. Dose reproducibility was verified per BS EN 60601-2-8:2015+A1:2016. Output measurements were validated against AAPM and IPEMB dosimetry protocols at the National Physics Laboratory UK.

Technological Characteristics

Low energy X-ray therapy system (10-80kV). Components: Varex VF-80 X-ray tube, Spellman generator, air-cooled water-cooling system. Applicators: Clear Cast Acrylic (PMMA). Filters: Aluminum (1.5mm/2.5mm). Connectivity: Standalone system with room interlocks. Software: Concerto v2.3, Fisica v1.06, TP2 v1.24. Standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-2-8, IEC 60601-1-6, IEC 62366, IEC 62304, ISO 14971.

Indications for Use

Indicated for superficial radiotherapy and surface electronic brachytherapy for patients with primary malignant epithelial neoplasms of the skin (Basal Cell Carcinoma, Squamous Cell Carcinoma, Metatypic Carcinoma, Cutaneous Appendage Carcinoma, Karposi's Sarcoma, Merkel Cell Carcinoma, Lentigo Maligna, Lentigo Maligna Melanoma, Cutaneous Lymphomas) and keloids.

Regulatory Classification

Identification

An x-ray radiation therapy system is a device intended to produce and control x-rays used for radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.

Predicate Devices

• X80 / RADiant / PhotoElectric Therapy System (K172080)

Submission Summary (Full Text)

{0}------------------------------------------------

July 13, 2023

Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Xstrahl Ltd. % Vineet Gupta Technical Director Unit 2 Maybrook Industrial Estate Maybrook Road Brownhills. West Midlands WS8 7DG UNITED KINGDOM

## Re: K230611

Trade/Device Name: X80 / RADiant / PhotoElectric Therapy System (RADiant Aura) Regulation Number: 21 CFR 892.5900 Regulation Name: X-Ray radiation therapy system Regulatory Class: Class II Product Code: JAD Dated: March 3, 2023 Received: March 6, 2023

## Dear Vineet Gupta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

{1}------------------------------------------------

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Image /page/1/Picture/5 description: The image shows a digital signature. The signature is for Lora D. Weidner. The date of the signature is 2023.07.13, and the time is 11:10:11 -04'00'.

Lora D. Weidner, Ph.D. Assistant Director Radiation Therapy Team DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K230611

Device Name

X80 / RADiant / Photoelectric Therapy System (RADiant Aura)

Indications for Use (Describe)

The Xstrahl Photoelectric Therapy System is a low energy X-Ray system intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Typical applications include treatment for Basal Cell Carcinoma, Squamous Cell Carcinoma, Metatypic Carcinoma, Cutaneous Appendage Carcinoma, Karposi's Sarcoma, Merkel Cell Carcinoma, Lentigo Maligna, Lentigo Maligna Melanoma, Cutaneous Lymphomas (B and T cell) and Keloids.

| Type of Use (Select one or both, as applicable) | |
|-----------------------------------------------------------------------------------------------------------|--|
| <span> <span style="font-size: 16px;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> | |
| <span> ☐ Over-The-Counter Use (21 CFR 801 Subpart C) </span> | |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Xstrahl. The logo consists of a purple oval shape with a white "X" inside of it, followed by the word "strahl" in purple. The font of the word "strahl" is sans-serif.

| Xstrahl Ltd Unit 2 Maybrook Industrial Estate Maybrook Road, Brownhills, West Midlands, WS8 7DG United Kingdom T [phone] E [e-mail]

Xstrahl.com

# 510(K) SUMMARY K230611

## A. SUBMITTERS NAME

Xstrahl Ltd.

FDA Establishment Registration No. 3004561814

#### B. ADDRESS

Unit 2, Maybrook Industrial Estate Maybrook Road Brownhills, West Midlands WS8 7DG United Kingdom

## C. CONTACT

| Name: | Vineet Gupta, Ph.D. |
|--------------|-------------------------|
| Designation: | Technical Director |
| Phone: | [phone] |
| Email: | [e-mail] |

#### D. DATE PREPARED:

3-March-2023

#### E. DEVICE NAME:

| Device Trade Name: | X80 / RADiant / PhotoElectric Therapy System |
|----------------------|----------------------------------------------|
| Classification Name: | X-Ray Radiation Therapy System |
| Model / Market Name: | RADiant Aura |

#### F. DEVICE CLASS:

| Device Class: | II |
|--------------------|----------------|
| Panel: | Radiology |
| Product Code: | JAD |
| Regulation Number: | 21CFR 892.5900 |

{4}------------------------------------------------

#### G. PREDICATE DEVICES:

X80 / RADiant / PhotoElectric Therapy System (K172080)

## H. STATEMENT ON INDICATIONS FOR USE:

The intended use and indications for use of the system have not changed due to the modification to the product. The modification has not changed the fundamental operating principle of the product.

#### Intended Use

The Xstrahl Photoelectric Therapy System is a low energy X-Ray system intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

#### Indications for Use

The Xstrahl Photoelectric Therapy System is a low energy X-Ray system intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Typical applications include treatment for Basal Cell Carcinoma, Squamous Cell Carcinoma, Metatypic Carcinoma, Cutaneous Appendage Carcinoma, Karposi's Sarcoma, Merkel Cell Carcinoma, Lentigo Maligna, Lentigo Maligna Melanoma, Cutaneous Lymphomas (B and T cell) and Keloids.

#### DEVICE DESCRIPTION: I.

The X80 / RADiant / Photoelectric Therapy System (hereafter referred to as the RADiant System) is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

The RADiant System is a standalone X-Ray radiation therapy system consisting of the X-Ray Therapy Unit, a TP2 Central Control Unit (CCU), a Control POD (Control POD), and a PC on which user interface software is loaded. The system has a time-based control system used with treatment filters and applicators. A range of bespoke treatment applicators and beam filters are available for use with the RADiant System.

The system is freestanding, self-contained, unobtrusive, compact and ergonomic in design, which helps to ensure a reassuring and stress-free patient experience. The system is floor mounted in order to accommodate almost any clinical space, and features ergonomically designed controls ensuring smooth adjustment and safe, simple patient set-up. The system requires connection to the clinical facilities electrical supply and room interlocks.

The system is intended for use within a hospital or other clinical environment where the patient is treated under 'outpatient' conditions by trained medical professionals only e.g. Radiographers, Clinicians and Oncologists. It is not intended for use by a patient or general public. The clinical environment typically consists of a safety-interlocked lead lined shielded Treatment Room housing the X-Ray Therapy Unit, the TP2 Central Control Unit and an Emergency Stop Button, with a Control Room housing the Control POD

{5}------------------------------------------------

and the PC. Door interlocks and warning lights are located at the access point to the treatment room. The operator is located outside the treatment room during the treatment process.

## J. PREDICATE DEVICE INFORMATION:

The RADiant Aura system is substantially equivalent to its primary predicate device RADiant (K172080; Decision Date: 29-September-2017).

The fundamental scientific technology of the RADiant Aura System with respect to its predicate device (RADiant system) has not changed. The intended use and indications for use of the device have not changed. Based upon the performance testing results for RADiant Aura (as detailed in the submission), the system raises no new issues of safety or effectiveness.

## K. COMPARISON TO THE PREDICATE DEVICE:

This section provides the summary of comparison of the RADiant Aura system to its predicate device.

| Sr. No. | Comparison<br>Item | Subject Device<br>RADiant Aura (X80 / RADiant /<br>Photoelectric Therapy System)<br>(K230611) | Predicate Device<br>X80 / RADiant / Photoelectric<br>Therapy System<br>(K172080) |
|--------------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Intended Use | The Xstrahl Photoelectric Therapy<br>System is a low energy X-Ray system<br>intended for superficial radiotherapy<br>and surface electronic brachytherapy<br>treatment of primary malignant<br>epithelial neoplasms of the skin and<br>keloids. | The Xstrahl Photoelectric Therapy<br>System is a low energy X-Ray system<br>intended for superficial radiotherapy<br>and surface electronic brachytherapy<br>treatment of primary malignant<br>epithelial neoplasms of the skin and<br>keloids. |
| 2. | Indications for<br>Use | The Xstrahl Photoelectric Therapy<br>System is a low energy X-Ray system<br>intended for superficial radiotherapy<br>and surface electronic brachytherapy<br>treatment of primary malignant<br>epithelial neoplasms of the skin and<br>keloids. | The Xstrahl Photoelectric Therapy<br>System is a low energy X-Ray system<br>intended for superficial radiotherapy<br>and surface electronic brachytherapy<br>treatment of primary malignant<br>epithelial neoplasms of the skin and<br>keloids. |
| | | Typical applications include treatment<br>for Basal Cell Carcinoma, Squamous<br>Cell Carcinoma, Metatypic Carcinoma,<br>Cutaneous Appendage Carcinoma,<br>Karposi's Sarcoma, Merkel Cell<br>Carcinoma, Lentigo Maligna, Lentigo<br>Maligna Melanoma, Cutaneous<br>Lymphomas (B and T cell) and<br>Keloids. | Typical applications include treatment<br>for Basal Cell Carcinoma, Squamous<br>Cell Carcinoma, Metatypic Carcinoma,<br>Cutaneous Appendage Carcinoma,<br>Karposi's Sarcoma, Merkel Cell<br>Carcinoma, Lentigo Maligna, Lentigo<br>Maligna Melanoma, Cutaneous<br>Lymphomas (B and T cell) and<br>Keloids. |
| 3. | FDA Product<br>Code | JAD | JAD |
| Sr. No. | Comparison<br>Item | Subject Device<br>RADiant Aura (X80 / RADiant /<br>Photoelectric Therapy System)<br>(K230611) | Predicate Device<br>X80 / RADiant / Photoelectric<br>Therapy System<br>(K172080) |
| 4. | FDA Class | II | II |
| 5. | FDA<br>Classification<br>Name | X-Ray Radiation Therapy System | X-Ray Radiation Therapy System |
| 6. | FDA Regulation<br>Number | 21CFR 892.5900 | 21CFR 892.5900 |
| 7. | Physical Characteristics | | |
| 7a. | Basic Design | Base unit, with 4 lockable wheels,<br>contains the x-ray generator and cooler.<br>X-Ray tube head is mounted on a<br>support arm that is mounted on the base<br>unit. | Base unit, with 4 lockable wheels,<br>contains the x-ray generator and<br>cooler. X-Ray tube head is mounted<br>on a support arm that is mounted on<br>the base unit. |
| 7b. | Base Unit<br>Dimension | 52 cm (D) x 57 cm (W) x 55 cm (H) | 52 cm (D) x 57 cm (W) x 55 cm (H) |
| 7c. | CCU Dimension | 28 cm (W) x 140 cm (H) x 170 cm (D) | 28 cm (W) x 140 cm (H) x 170 cm (D) |
| 7d. | POD Dimension | 20 cm (W) x 7.5 cm (H) x 150 cm (D) | 20 cm (W) x 7.5 cm (H) x 150 cm (D) |
| 8. | ARM Specifications | | |
| 8a. | Maximum Weight<br>Supported | 8 kg | 4.5 kg |
| 8b. | Rotation about the<br>base unit | $\pm 95°$<br>(Total rotation is the same with<br>reference to 0 degrees) | $\pm 180°$<br>(Total rotation is the same with<br>reference to 0 degrees) |
| 8c. | Vertical Range | 125.7 cm to -23 cm | 59.5 cm to -23 cm |
| 8d. | Horizontal Range | 8.5 cm to 118 cm | 43 cm to 105 cm |
| 8e. | Number of<br>electromagnetic<br>brakes | 2 (1 between vertical arm and base unit<br>and 1 between vertical and horizontal<br>arm) | 2 (1 between vertical arm and base unit<br>and 1 between vertical and horizontal<br>arm) |
| 8f. | Number of gas<br>struts | 4 (all 4 of them in the vertical arm: two<br>of them to control the vertical arm<br>motion and two of them to control the<br>horizontal arm motion) | 2 (one in vertical arm and 1 in<br>horizontal arm) |
| 9. | X-Ray Tube Head Specifications | | |
| 9a. | X-Ray Tube<br>Manufacturer | Varex Imaging | Varex Imaging |
| 9b. | Source Voltage | 10 kV to 80 kV | 10 kV to 80 kV |
| 9c. | Model Number | VF-80 | VF-80 |
| 9d. | Continuous Max<br>Tube Power | 100 W | 100 W |
| 9d. | Rotation of the<br>Tube Head | $\pm 110°$ | $\pm 90°$ |
| 9e. | Tilt of the Tube<br>Head | $\pm 45°$ | + 90° to - 15° |
| 9f. | Vertical Motion | 0-1 cm | None |
| 9e. | Number of<br>Electromechanical<br>Brakes | 2 (one to control the head rotation and<br>the other to control the head tilt) | None. This is based on a single<br>mechanical locking mechanism |
| Sr. No. | Comparison Item | Subject Device<br>RADiant Aura (X80 / RADiant /<br>Photoelectric Therapy System)<br>(K230611) | Predicate Device<br>X80 / RADiant / Photoelectric<br>Therapy System<br>(K172080) |
| 9f. | Image of Tube Head and controls | Image: Tube head and controls of RADiant Aura (X80 / RADiant / Photoelectric Therapy System) (K230611)<br><br>1. Tube head movement handle<br>2. Tube head vertical movement handle<br>3. Movement enable button for arm and head joints movement. Either button can be used.<br>4. LED light ring switch | Image: Tube head and controls of X80 / RADiant / Photoelectric Therapy System (K172080)<br><br>• Brake Button is the movement enable button for the arm joints movement<br>• Thumb screw is the mechanical locking mechanism for head movement |
| 10. | Image showing arm and head movement labels | Image: Arm and head movement labels of RADiant Aura (X80 / RADiant / Photoelectric Therapy System) (K230611) | Image: Arm and head movement labels of X80 / RADiant / Photoelectric Therapy System (K172080) |
| 11. | Base Unit Components | | |
| 11a. | X-Ray Generator | Spellman<br>Power: 100 W<br>KV Range: 0 to 80 kV<br>mA Range: 0 to 2 mA | Spellman<br>Power: 100W<br>KV Range: 0 to 80 kV<br>mA Range: 0 to 2 mA |
| 11b. | Cooling System | Type: Air-cooled water-cooling system<br>Pump: Laing D5-Pump 12V D5-Vario<br>Fan: 2 off 120 mm Noctua | Type: Air-cooled water-cooling system<br>Pump: Laing D5-Pump 12V D5-Vario<br>Fan: 180mm Silverstone |
| 11c. | Number of PCBs in the Base Unit | 2 | 5 |
| 12. | Applicators | | |
| 12a. | Max Focal Spot Distance (FSD) supported | 10 cm | 10 cm |
| 12b. | Standard Applicator kit | Electronic Brachytherapy: 5 cm FSD (1 cm, 1.5 cm, 2 cm, 3 cm, 4 cm)<br>Superficial Radiation Therapy: 6 cm FSD (1 cm, 1.5 cm, 2 cm, 3 cm, 4 cm) | Electronic Brachytherapy: 5 cm FSD (1 cm, 1.5 cm, 2 cm, 3 cm, 4 cm)<br>Superficial Radiation Therapy: 6 cm FSD (1 cm, 1.5 cm, 2 cm, 3 cm, 4 cm) |
| Sr. No. | Comparison<br>Item | Subject Device<br>RADiant Aura (X80 / RADiant /<br>Photoelectric Therapy System)<br>(K230611) | Predicate Device<br>X80 / RADiant / Photoelectric<br>Therapy System<br>(K172080) |
| 12c. | Applicator<br>Material | Clear Cast Acrylic (PMMA) | Clear Cast Acrylic (PMMA) |
| 13. | | Filters | |
| 13a. | Filter Material | Aluminum | Aluminum |
| 13b. | Standard Filter<br>thickness | 2.5 mm Al and 1.5 mm Al | 2.5 mm Al and 1.5 mm Al |
| 14. Software | | | |
| 14a. | Concerto | Version: 2.3 | Version: 2.3 |
| 14b. | Fisica | Version: 1.06 | Version: 1.06 |
| 14c. | TP2 | Version: 1.24 | Version: 1.24 |
| 15. | System Image | Image: System Image | |
| 16. | Overall System<br>Architecture | Image: Overall System Architecture | |

#### Table 1: Comparison of the Subject Device with Predicate Device

{6}------------------------------------------------

{7}------------------------------------------------

{8}------------------------------------------------

RADiant Aura contains all the features and components for the system as present in the predicate device. RADiant Aura enhances the design of the arm and the head joint of the system. The similarities and differences are described in detail as part of this submission.

RADiant Aura's (subject device (K230611) fundamental technological characteristics are the same as those of the predicate device (K172080). The x-ray tube (VF-80) and the generator (Spellman) used on both the systems are the same. The control system on the subject device (K230611) and the predicate device (K172080) is also the same. The firmware and the software used on both the devices (predicate (K172080) and subject (K230611)) are also the same. The overall system architecture of both the systems is also the same.

In addition, the target population and the indications for use are similar to that of the predicate device. Any minor differences in the features do not raise any concerns for safety, performance, or effectiveness of the

{9}------------------------------------------------

device. The characteristics / features of RADiant Aura with respect to the predicate device is described in the comparison chart in the submission.

## L. SUMMARY OF TESTING:

Design verification and validation testing was performed to ensure that the device functionality works as per its intended use, all risks are mitigated, is substantially equivalent, and the product conforms to the required standards.

Non-clinical testing, including verification of risk control measures, was completed and detailed results of these tests are included as part of this submission. Twenty Six independent verification tests and 18 independent validation tests were executed on the RADiant Aura systems. These tests included testing the system for its retention of the applicator and filter during various ranges of motion, residual motion of the system, system's response to power loss, system stability testing, radiation leakage testing, build of the individual components and the complete system. Software run-through functionality test was also completed successfully. The versions of the software used in predicate device (K17208) worked without any changes with the RADiant Aura system. Testing was also completed to ensure that the system's ability to position the treatment head to treat different locations while the patient was laying on the bed or was in seated position was not affected by the design changes with respect to the predicate device.

Testing was also completed successfully that determined the dose reproducibility in accordance with BS EN 60601-2-8:2015+A1:2016 clause 201.10.1.2.112 'Agreement between indicated values and effective values.'

In addition, independent output measurements were completed successfully at the National Physics Laboratory UK (NPL) as per Xstrahl Customer Acceptance Test procedure and to verify compliance with the following recognized codes of practice:

- AAPM. (2001). AAPM protocol for 40-300kV x-ray beam dosimetry in radiotherapy and o radiobiology.
- IPEMB. (1996). The IPEMB code of practice for the determination of absorbed dose for x-rays O below 300kV generating potential (0.035 mm Al-4 mm Cu HVL: 10-300kV generating potential).

#### Conclusion:

The verification and validation results demonstrate that the RADiant Aura system met its design requirements and specifications, is substantially equivalent to its predicate device, and conforms to the applicable sections of standards that includes:

- . IEC 60601-1: Medical Electrical Equipment – General Requirements for basic safety and essential performance
- IEC 60601-1-2: Medical electrical equipment Part 1-2: General requirements for basic safety and . essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests
- . IEC 60601-2-8: Medical electrical equipment - Part 2-8: Particular requirements for the safety of therapeutic X-ray equipment operating in the range 10 kV to 1 MV
- IEC 60601-1-6: Medical electrical equipment Part 1-6: General requirements for basic safety and ● essential performance - Collateral standard: Usability
- IEC 62366: Medical devices Part 1: Application of usability engineering to medical devices ●
- IEC 62304: Medical device software Software life cycle processes ●
- ISO 14971: Medical devices Application of risk management to medical devices ●